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Abstract: Background: High-intensity smoking cessation programs generally lead to more 
continuous abstinence, however, lower rates of success have been reported among heavy 
smokers. The aim was to evaluate continuous abstinence among heavy smokers during the 
intensive 6-week Gold Standard Program (GSP) and to identify modifiable factors 
associated with continuous abstinence. Methods: In this nationwide clinical study based on 
36,550 smokers attending an intensive cessation program in Denmark. Heavy smoking was 
defined as ≥7 points in the Fagerström Nicotine Dependency Test, smoking ≥20 cigarettes 
daily or ≥20 pack-years. Results: Overall, 28% had a Fagerström score  
≥7 points, 58% smoked ≥20 cigarettes daily and 68% smoked ≥20 pack-years. Continuous 
abstinence was 33% in responders (6-months response rate: 78%); however, abstinence 
was approximately 1–6% lower in the heavy smokers than the overall population. 
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Attending GSP with an individual format (vs. group/other, OR 1.23–1.44); in a hospital 
setting (vs. pharmacy/municipality services, OR 1.05–1.11); and being compliant 
(attending the planned meetings OR 4.36–4.89) were associated with abstinence. 
Abstinence decreased in a dose-dependent manner with increasing smoking severity. 
Conclusions: Abstinence after GSP was 1–6% lower in the heavy smokers than in the 
overall study population. Modifiable factors may be used for small improvements in 
continued abstinence. However attempts to improve compliance seemed especially promising. 
Keywords: smoking cessation; abstinence; heavy smokers; intensive program;  
nationwide database; group program; individual program; Denmark 
 
1. Introduction 
The health consequences of severe tobacco addiction and an increased rate of tobacco consumption 
are tremendous [1,2]. There are no generally agreed-upon definitions of heavy smoking, but a 
cumulative dose of 73,000–146,000 cigarettes, which corresponds to 20 cigarettes per day over  
10–20 years, or 10–20 pack-years, is associated with a clinically relevant increase in morbidity [1–3]. 
For clinical purposes, the Fagerström Test for Nicotine Dependence (FTND) [4] and daily cigarette 
consumption are two measures that are frequently used to guide therapy. The cut-off values of  
4 to 7 points (10 points max) and 15, 20 or 25 cigarettes per day often define heavy smokers [5–12]. 
Heavy smokers are less likely to successfully quit smoking [6,7,12–15], but pharmacotherapy 
tailored to the individual level of dependency increases sustained abstinence, especially in patients 
with a high dependency [9,16]. More intensive and longer-lasting smoking cessation programs results 
in higher rates of continuous abstinence than less intensive interventions, such as brief advice or 
motivational interviews [2,16–22]. 
The most frequently used intensive intervention program in Denmark is manual-based. The Danish 
Cancer Society teaches and trains counsellors nationwide for the program. It is offered in a variety of 
public and private settings, including hospitals, pharmacies and municipalities/counties throughout the 
Danish regions; the programs differed with respect to format (group or individual) and the modality of 
payment [6,7,10,23–27]. 
The setting, locality, format and program payment, as well as gender, age and social status may 
influence the success rate of continued abstinence. How heavy smokers benefit from intensive 
programs can be evaluated using the comprehensive data from the Danish Smoking Cessation 
Database [23]. 
Therefore, the aims of this study were to evaluate the continuous abstinence among heavy smokers 
who underwent a standardized intensive smoking cessation program that was integrated with 
pharmacotherapy and to identify whether modifiable factors related to the program were associated 
with continuous abstinence. Smoking at least 20 cigarettes daily, scoring at least 7 FTND points and 
accumulating at least 20 pack-years were the characteristics used to define heavy smokers in this study. 
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To identify the most relevant definition of heavy smokers according to the outcome after the 
intensive smoking cessation program, a secondary aim evaluated whether continuous abstinence was 
associated with smoking severity. 
2. Experimental Section 
2.1. Study Design 
We used a prospective observational study based on a nationwide registry that was established in 
2001 to continuously collect data from smoking cessation programs; the data were delivered by the 
smoking cessation units and included individual follow-up information on continuous abstinence after 
6 months. The data were collected until the summer of 2011 [23,26,27]. This project was approved by 
the Danish Data Protection Agency (2010-41-5463/2000-54-0013) and registered with the Scientific 
Ethical Committee (H-C-FSP-2010-049). 
2.2. Outcomes 
The primary outcome was continuous abstinence from the intended quit date until 6 months after 
that date; the last treatment date was used for the cases without an intended quit date. The information 
on quit rate was collected by questionnaires (mail or telephone) 6 months after the intended quit date; 
after 2006, these data were exclusively collected by telephone. From 2001 to 2005, at least one 
reminder was sent. After 2006, the standard operating procedure included four attempts to reach the 
patient, at least one of which was in the evening. Continued abstinence until the 6 month time point 
(±1 month) was documented. The secondary outcome was point prevalence at 6 months of  
non-smoking considering a period of 14 days in 2006 to 2010 and 7 days in 2001–2005. 
2.3. Participants 
After providing informed consent, the patients were registered in the Smoking Cessation Database 
and were included in this study. Among the 67,151 registered interventions from 2001 to 2010, the 
following were excluded from the study: 1,723 patients because information on their follow-up visits 
from the last 7 months of the study were not yet available; 76 patients from Greenland; 6,325 patients 
who did not attend the standardized intensive program; 604 adolescents who were under 18 years of 
age; and 300 patients who did not provide their age. In addition, the following were also excluded: 
1,919 patients who were missing nicotine dependence values; 1,029 patients whose records were 
missing the number of daily cigarettes; 717 patients who did not list the number of years they had been 
smoking (resulting in 1,439 patients who were missing information about pack-years); and one patient 
missing gender information. In total, 55,568 patients had complete information. In addition, some of 
the smoking cessation units did not follow-up with their patients after 6 months; therefore, patients 
from these units (n = 19,018) were not included in these analyses (Figure 1). 
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Figure 1. Trial profile. 
 
There was no information about the patients’ personal identification number prior to 2006. 
Therefore, multiple entries could not be sorted. Approximately 4% of the documented interventions 
were from patients who had attended a program more than once [27]. 
2.4. Setting 
During this 10-year study, more than 300 smoking cessation units in Denmark, including those in 
different settings such as hospitals, primary care and municipality clinics, pharmacies and other private 
settings, contributed data to the smoking cessation database. In 2007, Denmark was divided into  
5 Danish Health Regions corresponding to 14 counties [26]. 
2.5. Intervention 
Intensive smoking cessation programs have been standard for smoking intervention in Denmark 
since 2001. These programs are manual-based teaching sessions (6-week sessions with 5–6 meetings 
in a group or individual format) with individual pharmocotherapy according to the level of dependence 
(e.g., individually tailored nicotine replacement therapy according to nicotine dependence measured by 
Fagerström Score [4], vareniclin or bupropion). These programs were originally developed under the 
direction of the National Cancer Society together with the previous “National Stop Smoking  
Centre” [6,7,10,26,27]. The program included a curriculum with topics such as readiness to change and 
setting a quit date, ambivalence and motivation, withdrawal symptoms and nicotine replacement 
therapy, relapse prevention and living completely smoke-free. The programs were usually offered free 
of charge; most of the patients paid for their medication, but a few received free medication. 
Furthermore, a hotline was available during daytime hours on working days. 
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2.6. Data 
Data were collected on an individual’s socio-demographic parameters, smoking history, their 
intervention program and follow-up results (Table 1). 
Table 1. Characteristics of the study population allover and by heavy smoking definition
 a
, 
with continuous abstinence rates for the group of patients responding to follow up (base) 
and under two scenarios: (1) assuming non-responders relapsed (worst case), and  
(2) assuming non-responders abstained (best case). 
 All Fagerström score ≥ 7 Cigarettes/day ≥ 20 Pack years ≥ 20 
 n =  base (worst-best) n =  base (worst-best) n =  base (worst-best) n =  base (worst-best) 
Total 36,550 33% (26%–48%) 10,237 27% (21%–45%) 21,065 30% (23%–46%) 24,247 32% (25%–46%) 
Capital Region 12,100 32% (25%–48%) 3,504 26% (20%–45%) 7,293 30% (23%–46%) 8,010 31% (24%–46%) 
Central Denmark 8,216 33% (25%–48%) 2,183 27% (20%–45%) 4,419 29% (22%–45%) 5,200 32% (25%–46%) 
North Denmark 1,477 36% (29%–50%) 368 30% (24%–46%) 780 33% (26%–48%) 982 36% (29%–48%) 
Region Zealand 5,144 34% (28%–47%) 1,512 29% (23%–43%) 3,149 32% (26%–44%) 3,687 33% (28%–44%) 
South Denmark 9,613 34% (27%–48%) 2,670 27% (21%–45%) 5,424 31% (24%–47%) 6,368 32% (26%–46%) 
Unknown 0            
Pharmacy 9,664 33% (26%–48%) 2,749 27% (20%–44%) 5,592 29% (23%–45%) 6,789 31% (25%–45%) 
Hospital 7,813 36% (28%–50%) 2,475 30% (22%–47%) 4,610 33% (25%–49%) 5,040 35% (27%–49%) 
All other settings 19,073 32% (25%–47%) 5,013 27% (20%–44%) 10,863 30% (23%–45%) 12,418 31% (25%–45%) 
Individual format 4,526 37% (27%–53%) 1,439 34% (24%–53%) 2,612 34% (25%–52%) 2,931 35% (27%–51%) 
Group format 31,918 33% (26%–47%) 8,773 26% (20%–43%) 18,401 30% (23%–45%) 21,260 32% (25%–45%) 
All other formats 106   25   52   56   
No free medication/other 15,112 33% (26%–47%) 3,894 27% (21%–43%) 8,400 30% (24%–44%) 10,008 32% (26%–44%) 
Free medication for days 16,478 32% (25%–48%) 4,766 26% (20%–45%) 9,722 29% (22%–46%) 10,904 31% (25%–46%) 
Free for <5 weeks 4,026 36% (27%–50%) 1,293 31% (24%–48%) 2,416 34% (26%–50%) 2,775 35% (28%–49%) 
Free for the total course 934 40% (32%–53%) 284 35% (27%–50%) 527 37% (29%–51%) 560 36% (30%–48%) 
Women 22,538 32% (25%–46%) 5,620 25% (19%–42%) 11,423 27% (21%–43%) 13,851 29% (24%–43%) 
Men 14,012 36% (28%–50%) 4,617 30% (23%–48%) 9,642 34% (26%–49%) 10,396 36% (28%–49%) 
Unknown 0            
18-24 years age 1,407 26% (17%–54%) 280 19% (11%–53%) 626 22% (14%–52%) 7 – – – 
25-34 years 4,855 32% (23%–50%) 1,164 23% (16%–46%) 2,341 28% (20%–49%) 683 26% (19%–46%) 
35-44 years 8,038 33% (25%–48%) 2,446 26% (19%–45%) 4,710 29% (22%–46%) 4,784 29% (22%–46%) 
45-54 years 10,135 33% (26%–47%) 3,277 27% (21%–44%) 6,316 30% (23%–45%) 8,207 31% (25%–46%) 
55-64 years 8,946 35% (29%–47%) 2,524 30% (24%–44%) 5,492 33% (27%–45%) 7,851 34% (28%–46%) 
65+ years 3,169 34% (28%–46%) 546 32% (26%–45%) 1,580 33% (27%–45%) 2,715 33% (27%–45%) 
Unknown 0            
No previous attempt 13,168 32% (25%–47%) 4,323 27% (20%–45%) 8,351 30% (23%–46%) 9,371 32% (25%–46%) 
Previous attempt 22,741 34% (27%–48%) 5,703 27% (21%–44%) 12,332 30% (24%–46%) 14,395 32% (26%–46%) 
Unknown 641   211   382   481   
Living with smoker 13,291 32% (25%–46%) 3,912 27% (21%–43%) 8,059 30% (23%–45%) 8,762 31% (25%–51%) 
Not living with smoker 22,975 34% (26%–49%) 6,233 28% (21%–45%) 12,825 31% (23%–47%) 15,293 32% (25%–47%) 
Unknown 284   92   181   192   
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Table 1. Cont. 
 All Fagerström score ≥ 7 Cigarettes/day ≥ 20 Pack years ≥ 20 
 n =  base (worst-best) n =  base (worst-best) n =  base (worst-best) n =  base (worst-best) 
Compliant 23,400 42% (34%–52%) 6,144 37% (30%–49%) 12,990 40% (32%–51%) 15,919 40% (34%–50%) 
Not compliant 12,677 15% (11%–40%) 3,968 10% (7%–39%) 7,805 12% (9%–38%) 8,032 13% (9%–37%) 
Unknown 473   125   270   296   
Employed 24,677 34% (27%–49% 6,694 29% (22%–45%) 14,040 31% (24%–47%) 15,477 33% (26%–47%)  
Not employed 10,941 31% (24%–46%) 3,285 24% (18%–44%) 7,025 28% (22%–44%) 8,770 30% (24%–45%) 
Unknown 698   195   395   465   
2006-2010 21,516 33% (26%–46%) 5,577 27% (21%–43%) 12,172 29% (23%–44%) 14,011 31% (25%–44%) 
2001-2005 15,034 34% (26%–50%) 4,660 28% (21%–47%) 8,893 31% (24%–48%) 10,236 33% (26%–48%) 
Unknown 0            
a Heavy smokers: Fagerström Test for Nicotine dependence score of at least 7, or smoking at least  
20 cigarettes per day (20 CPD) or at least 20 pack years. 
Program compliance was defined as having attended at least 75% of the scheduled meetings, as 
documented by the units. To account for possible administrative effects and historical, social and 
technical changes in the setting, which included a reform of the healthcare system in 2007, the study 
period was categorized as “2001–2005” and “2006–2010”. 
2.7. Statistical Methods 
Continuous abstinence was used based on the patients’ self-reports. To compare the results from 
this observational prospective study with results from randomized controlled studies, the abstinence 
was reported according to the Russell criteria [28], assuming in the worst case that all non-responders 
had relapsed. The best case results assumed that none of the non-responders had relapsed. These 
assumptions were used to estimate the range of confidence. 
Multiple logistic regression analyses were used to test for differences in quit rates by first entering 
all of the predictors together, followed by a stepwise backward procedure with the criterion  
P(in) < 0.10. The results were presented as odds ratios (OR) and the corresponding 95% confidence 
intervals (CI). The results were considered significant if the CI did not include the value 1. For the 
logistic regression, dummy variables as independent variables were used, as outlined in Table 1. 
To evaluate the relationship between the quit rate and smoking severity using secondary analysis, 
patients were categorized by their smoking severity according to the FTND [4,14], the number of daily 
cigarettes smoked and the number of pack-years as shown in Figure 2. 
In addition, the entry characteristics of the patients included in the primary outcome analyses were 
compared with those of the patients not included in the analyses. All statistical calculations were 
performed using PASW 19 (IBM Corporation, Somers, NY, USA). 
  
Int. J. Environ. Res. Public Health 2013, 10 4192 
 
 
Figure 2. Odds ratio () and 95% CI (▬) of continuous abstinence as the dependent 
variable for Fagerström points (FTND), cigarettes per day (CPD) and pack-year after 
adjusting (final model) for setting, region, format, payment modality, age, gender, 
employment, attempts to quit, living with a smoker, compliance and calendar period. 
 
 
 
3. Results 
Documented follow-up data were available for 28,542 interventions for the responding patients 
(Figure 1); among these, 28% reported 7 or more points on the FTND scale, 58% had smoked  
at least 20 cigarettes per day and 68% smoked at least 20 pack-years, thereby fulfilling the criteria for 
heavy smoking. 
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The patient characteristics are shown in Table 1. The analyses for the 6-month follow-up visit 
included both the responders and the non-responders; out of all the responding patients, 9,490 (33%) 
reported continuous abstinence. The “worst case” quit rate, when all of the non-responders were 
considered smokers, was 26%. However, the “best case” quit rate, when all of the non-responders were 
considered non-smokers, was 48%. 
The heavy smokers had a significantly lower rate of continuous abstinence compared with the 33% 
abstinence in all of the patients; there was a 6% (2–9% in the subgroups) difference in the Fagerström 
Tests of the patients with at least 7 points; 3% (1–5%) difference in the smokers that smoked at least 
20 cigarettes per day; and 1% (0–4%) for that smoked at least 20 pack-years (Table 1). The results of 
the multivariate analysis for the heavy smokers are shown in Table 2. 
Table 2. Multivariate model and final model after backward elimination for continuous 
abstinence as the dependent variable. The independent categorical variables were given 
with the reference category in brackets. (Significant results were additionally marked with 
an * asterisk.) 
 Fagerström score ≥ 7 Cigarettes/day ≥ 20 Pack years ≥ 20 
 ORs (95% CI) Exp(B) (95% CI) Exp(B) (95% CI) 
MULTIVARIATE    
Capital (vs. other regions) 0.99 (0.87–1.13) 1.00 (0.92–1.08) 0.94 (0.87–1.01) 
(Setting)  * * 
Pharmacy (vs. other settings) 0.89 (0.78–1.02) 0.91 (0.83–0.99) * 0.90 (0.83–0.98) * 
Hospital (vs. other settings) 1.05 (0.91–1.22) 1.11 (1.01–1.23) * 1.10 (1.00–1.20) * 
Pharmacy (vs. hospitals) 0.85 (0.72–1.00) 0.82 (0.73–0.91) * 0.82 (0.74–0.91) * 
Individual (vs. other formats) 1.44 (1.23–1.68) * 1.29 (1.15–1.44) * 1.22 (1.10–1.35) * 
Payment for weeks (vs. non/shorter payments) 1.06 (0.78–1.43) 1.08 (0.87–1.34) 0.98 (0.80–1.20) 
Men (vs. women) 1.25 (1.12–1.39) * 1.31 (1.22–1.41) * 1.29 (1.21–1.38) * 
Age ( every 10 years) 1.07 (1.02–1.13) * 1.05 (1.02–1.09) * 1.10 (1.06–1.14) * 
Compliant (vs. other) 4.90 (4.28–5.61) * 4.38 (4.01–4.78) * 4.35 (4.01–4.73) * 
Living with a smoker (vs. not) 0.94 (0.84–1.05) 0.95 (0.89–1.03) 0.95 (0.89–1.01) 
No earlier attempts (vs. earlier attempts) 1.03 (0.93–1.15) 0.99 (0.92–1.07) 1.03 (0.97–1.10) 
Employed (vs. other) 1.28 (1.13–1.45) * 1.22 (1.12–1.33) * 1.25 (1.16–1.36) * 
2001–2005 (vs. 2006–2010) 0.85 (0.76–0.96) * 0.87 (0.80–0.94) * 0.88 (0.82–0.95) * 
Constant 0.08 * 0.10 * 0.09 * 
FINAL MODEL    
(Setting )  * * 
Pharmacy (vs. other settings) 0.90 (0.78–1.02) 0.91 (0.83–0.99) * 0.92 (0.85–0.99) * 
Hospital (vs. other settings) 1.05 (0.91–1.21) 1.11 (1.01–1.23) * 1.07 (0.98–1.17) 
Pharmacy (vs. hospitals) 0.85 (0.73–0.99) 0.81 (0.73–0.90) * 0.86 (0.78–0.94) * 
Individual (vs. other formats) 1.44 (1.23–1.68) * 1.30 (1.16–1.45) * 1.23 (1.11–1.36) * 
Men (vs. Women) 1.25 (1.12–1.39) * 1.31 (1.22–1.41) * 1.29 (1.21–1.38) * 
Age (every 10 years) 1.07 (1.02–1.13) * 1.05 (1.02–1.09) * 1.10 (1.06–1.14) * 
Compliant (vs. other) 4.89 (4.27–5.60) * 4.38 (4.01–4.78) * 4.36 (4.01–4.73) * 
Employed (vs. Other) 1.28 (1.13–1.44) * 1.22 (1.12–1.33) * 1.25 (1.16–1.35) * 
2001–2005 (vs. 2006–2010) 0.85 (0.76–0.95) * 0.87 (0.80–0.94) * 0.89 (0.83–0.95) * 
Constant 0.07 * 0.10 * 0.09 * 
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The final models suggest that an “individual format” was the only modifiable factor that was 
consistently associated with an increase in continuous abstinence after 6 months, regardless of which 
“heavy smoking” definition was used. The rate for continuous abstinence was higher among the 
patients who attended cessation programs in a hospital setting than among the patients who attended 
programs in pharmacies or community settings. However, results were not similar for the heavy 
smokers with at least 7 FTND points. Other indicators of continuous abstinence were male gender, 
increased age, high compliance, being employed and calendar period. 
3.1. Quit Rate and Severity of Smoking 
The rates for continuous abstinence differed substantially in a dose-response manner by level of 
smoking based on FTND score, ranging from 43% (34%–55%) in the group with 0–2 points to 27% 
(20%–46%) in the group with 9–10 points. Those in the different groups based on the number of 
cigarettes per day and pack-years had similar dose responses. The dose response was present for the 
unadjusted raw quit rates and for the odds ratios in the model that adjusted for age, gender, setting, 
format, region, payment modalities, number of previous attempts to quit, living with a smoker, 
compliance and calendar period (Figure 2). The overall continuous abstinence rate was 33%. 
Compared with this 33%, all of the patients with at least 5 FTND points, who smoked at least  
20 cigarettes per day or smoked at least 20 pack-years, had lower continuous abstinence rates. 
3.2. Point Prevalence 
Data on the point abstinence prevalence were available for 28,574 documented interventions. 
Overall, this point abstinence prevalence was approximately 4–5% higher than the continuous quit 
rate: 11,106 (overall, 39%; worst case, 30%; best case, 52%) interventions resulted in patient-reported 
point abstinence; the patients from 2001 to 2005 had a 7-day point abstinence prevalence of 38%, 
whereas the patients from 2006 to 2010 had a 14-day point abstinence prevalence of 39%. 
Overall, the point abstinence prevalence was significantly lower in the heavy smokers: 32%  
(25%–48%) in patients with 7–10 FTND points, 35% (28%–50%) in the group that smoked 20 or more 
cigarettes per day and 37% (30%–50%) in those reporting 20 or more pack-years. 
3.3. Sensitivity Analyses 
The proportion of non-responders was 22% (Figure 1). The sensitivity analyses showed that  
non-responders were more likely to be patients who attended individual programs (25%), young 
patients (18–24 years: 37%, 25–34 years: 27%), patients with low pack-years (0–10 years: 28%)  
and non-compliant patients (29%). By contrast, the proportion of non-responders was lower  
among the patients from Region Zealand (19%) and among the elderly patients (55–64 years: 19%,  
65 and more: 18%). 
Overall, 34% of the non-responders originated from units that did not perform patient follow-ups. 
Follow-up increased during the course of the study: only 58% of the patients who were registered prior 
to 2006 participated in the follow-ups, but 72% participated after 2006. Patients who originated from 
the units that did not have follow-up were mainly from regions outside of the Capital Region  
Int. J. Environ. Res. Public Health 2013, 10 4195 
 
 
(39% vs. 22% Capital region, p < 0.001), and they were more likely to attend individual programs 
(41% vs. 33%, p < 0.001) and were less likely to receive free medication (35% vs. 31%, p < 0.001). 
4. Discussion 
The present study had two main findings. First, this study showed that after attending intensive 
smoking cessation programs, heavy smokers had a 1–6% lower continuous abstinence rate than the 
33% overall quit rate. 
Continuous abstinence consistently decreased in a dose-dependent manner with increased smoking 
severity; the decrease in continuous abstinence was measured by the amount of cigarettes smoked per 
day, pack-years and nicotine dependency. These results highlight that no clear cut-offs exist for heavy 
smokers. Using 33% as the percent of patients who demonstrated continued abstinence, the cut-off 
value for the FTND score would be 5 instead of the 7 points used for the definition of heavy smoking 
in this paper. The other definitions used for heavy smokers would remain the same. The new cut-off 
values add to the many other definitions of heavy smoking [2,5–12] but are closely related to the 
intensity of the program, and other interventions may result in different cut-off points. 
In this study, compliance was defined as attending five education meetings and was the overall 
strongest predictor of a favourable outcome. In the literature, continuous abstinence is consistently 
associated with increased intervention duration [2,15,17,29,30]; however, our findings together with 
findings from randomized controlled trials underline the importance of completing the cessation 
program [16–22,31]. Other modifiable factors that were good predictors included an individual and 
hospital setting/format. 
Previously, group format and one-on-one settings were equally effective in achieving  
abstinence [18,19,31–33]. However, other reports suggested that the group format is superior [15,29]. 
In Denmark, nine out of 10 interventions are delivered in a group format, whereas in the UK, the group 
format is only used by a small percentage of treatment-seeking smokers [15,29,34]. Obstacles to 
delivering smoking cessation intervention in groups include patient preferences and organizational  
and feasibility issues [15,29,34]. However, these obstacles do not seem to be of equal importance  
in Denmark. 
In addition, non-modifiable factors, such as older age, male gender and not living with a smoker, 
were all associated with a higher rate of continuous abstinence after 6 months, which has been reported 
in previous studies [1,2,6,7,10,12,15,29,35–37]. 
To the best of our knowledge, this is the first study that addresses the impact of region, setting, 
format and payment modality on continuous abstinence in heavy smokers. 
In their daily practice, clinicians should ensure that smokers receive treatment to address  
not only smoking in general but also individual background. Clinicians should emphasize that 
completing an intensive program is associated with successful quitting for 1 out of 3 or 4 smokers, 
even the heavy smokers. 
This study had several limitations. Relevant selection, information availability, attrition bias and 
confounding must be considered. The allocation of a patient into a single patient format, setting, region 
or payment modality may have been influenced by factors not sufficiently addressed, as this was not a 
randomized controlled trial. In addition the outcomes were influenced by the study period which was 
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included in the analysis. In the later part of the study, more units conducted patient follow-ups, and 
guidelines changed from written follow up to follow up by phone. In addition, because all of the 
patients were treatment seekers and were registered in an intensive program within the Danish health 
system, the findings of this study may be limited in their generalizability to other heavy smokers. The 
continuous abstinence rates reported may be overestimated by approximately 3 to 6% [15,36,38,39] 
because this outcome relied on self-reports. The proportion of patients who did not respond to  
follow-ups was moderate, and the sensitivity analyses revealed a relatively robust finding. Few patients 
received free medications for more than a week, so it was not possible to draw conclusions about the 
potential benefits of providing free medications. Other factors that may have influenced the outcome 
but were not part of the study included co-morbidity, control of stress, tension, depressive or anxious 
moods, social support, motivation, and using smoking to control the body weight [5,35,37,40–44]. The 
proportion of patients attending a program more than once (approximately 4%) was considered small. 
Strength of this evaluation of smokers in intensive programs was that it included approximately 
90% of all smoking cessation intervention activities in Denmark. More than 1% of the total Danish 
population or more than 5% of all Danish smokers have been registered in this smoking cessation 
database to date, regardless of smoking severity, motivation to quit or co-morbidity or whether a  
quit-date was set. These characteristics are often used as selection criteria in randomized control  
trials [15,45]. Therefore, registry-based studies are needed to study smoking cessation interventions. 
Higher continuous abstinence rates are higher in more intensive programs [17,30] than in programs 
that are shorter in duration. In general, the reported differences in the continuous abstinence rates after 
smoking cessation intervention with respect to smoking severity vary greatly, from smaller clinically 
insignificant differences to differences exceeding a factor of 3 [4,9,14,15,46–48]. This difference may 
be due to the intensity of the programs or due to cultural differences, patient preferences, motivation, 
staff competencies and other factors. Finally, this study emphasizes that heavy smokers benefit from 
more intensive programs with individualized approaches than other programs. 
5. Conclusions 
Nationwide data delivered to the Danish Smoking Cessation Database by smoking cessation units 
which included individual follow-up information on continuous abstinence after 6 months 
demonstrated that abstinence after the intensive 6-week Gold Standard Program was 1–6% lower in 
the heavy smokers than in the overall study population. More heavy smokers report continuous 
abstinence after attending the planned meetings of intensive programs with individualized approaches 
compared to programs in a group format or compared to patients with a lower compliance. For some 
heavy smoking patients abstinence was higher in hospital programs and lower in pharmacy based 
programs. The likelihood of abstinence decreased also in a dose-dependent manner with increasing 
smoking severity. 
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